Traws Pharma (TRAW) announced that the planned test of tivoxavir marboxil in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency, or MHRA. “Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile consistent with its use for bird flu treatment and prevention,” said C. David Pauza, chief science officer for Traws Pharma, “The product candidate retains potential for emergency use in a bird flu outbreak and for prevention in high-risk populations.” The Company has a portfolio of back-up influenza antiviral compounds and is actively advancing candidates with TXM’s long-duration pharmacokinetic and antiviral profile and devoid of any mutagenic potential.” Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
